Cardiovascular Systems — Q4 FY2020 Earnings Presentation
7 slides from Cardiovascular Systems's earnings presentation, Aug 4, 2020
Slide 1: Q4 FY20 Earnings Call August 4, 2020
Q4 FY20 Earnings Call August 4, 2020
Slide 2: Safe Harbor Forward Looking Statements
Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem
Slide 3: Q4 Revenues of $42.5 Million, 38% Decrease
Q4 Revenues of $42.5 Million 38% Decrease ($ in millions) Revenues US Peripheral revenue declined 36% US Peripheral, US Coronary, US Coronary revenue $30.6 $9.8 declined 44% International, International decreased 17% $2.1 US Peripheral US Coronary International
Slide 4: Financial Results
Q4 FY20 Financial Results ($ in millions) Worldwide Peripheral Revenue Worldwide Coronary Revenue $48.3 $45.5 $47.6 $20.8 $42.6 $20.0 $19.0 $18.5 $30.6 36% $11.9 41% decline decline WW in Q4 WW in Q4 due to due to Covid-19 Covid-19 Q4 FY19 Q1 FY20 Q2 FY20 Q3 FY20 Q4 FY20 Q4 FY19 Q1 FY20 Q2 FY20 Q3 F
Slide 5: Highlights
Q4 FY20 Highlights Financial Operational - Peripheral Operational – Coronary Other Revenues -37.6% vs. LY • Use of low profile peripheral • Launching next gen coronary • Sold 14,500 OAS units offerings including Exchangeable OAS will facilitate cath lab • Over 1,200 medical Gross Margin 76.2% and Ra
Slide 6: Fiscal 2021 First Quarter Guidance
Fiscal 2021 First Quarter Guidance For the fiscal 2021 first quarter ending September 30, 2020, CSI anticipates: • Revenue of $55 million to $58 million, representing sequential revenue growth compared to the fourth quarter of fiscal 2020 of 29% to 36%; • Gross profit as a percentage of revenues in
Slide 7: Investor Contact
Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2020 Cardiovascular Systems, Inc. CSII OrbusNeich®, Teleport® and Sapphire® are trademarks
Cardiovascular Systems — Q4 FY2020 Earnings Presentation on 6ix